{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T19:21:46Z","timestamp":1768677706754,"version":"3.49.0"},"reference-count":13,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,10,22]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Five-year follow-up of S1106 demonstrates similar efficacy, MRD negativity, and 5-year survival with RH or RB, but RH was more toxic than RB. RB showed excellent efficacy and survival and less toxicity compared with a cytarabine-based regimen in transplant-eligible MCL patients.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000526","type":"journal-article","created":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T18:27:51Z","timestamp":1571768871000},"page":"3132-3135","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":22,"title":["Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma"],"prefix":"10.1182","volume":"3","author":[{"given":"Manali","family":"Kamdar","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, University of Colorado School of Medicine, Denver, CO;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongli","family":"Li","sequence":"additional","affiliation":[{"name":"SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Hematopoietic Cell Transplantation, City of Hope, Duarte, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M.","family":"Rimsza","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.","family":"Leblanc","sequence":"additional","affiliation":[{"name":"SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy S.","family":"Fenske","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas C.","family":"Shea","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9733-401X","authenticated-orcid":false,"given":"Paul M.","family":"Barr","sequence":"additional","affiliation":[{"name":"James P. Wilmot Cancer Center, Division of Hematology and Oncology, University of Rochester, Rochester, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tycel J.","family":"Phillips","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Michigan Cancer Center, Dexter, MI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brad S.","family":"Kahl","sequence":"additional","affiliation":[{"name":"Department of Medicine, Washington University School of Medicine, St. Louis, MO;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[{"name":"Wilmot Cancer Institute, University of Rochester, Rochester, NY; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonali M.","family":"Smith","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2019,10,22]]},"reference":[{"issue":"11","key":"2019111520524154000_B1","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","article-title":"Mantle cell lymphoma","volume":"34","author":"Cheah","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111520524154000_B2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/bjh.14699","article-title":"Incidence and survival trends in mantle cell lymphoma","volume":"181","author":"Epperla","year":"2018","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111520524154000_B3","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.23608","article-title":"Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004","volume":"113","author":"Zhou","year":"2008","journal-title":"Cancer"},{"issue":"7","key":"2019111520524154000_B4","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"issue":"10044","key":"2019111520524154000_B5","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"issue":"16","key":"2019111520524154000_B6","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"issue":"9873","key":"2019111520524154000_B7","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"12","key":"2019111520524154000_B8","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2019111520524154000_B9","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1200\/JCO.2017.35.15_suppl.7501","article-title":"Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study [abstract]","volume":"35","author":"Rummel","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111520524154000_B10","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/bjh.14480","article-title":"RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106","volume":"176","author":"Chen","year":"2017","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111520524154000_B11","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111520524154000_B12","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":"Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma","volume":"107","author":"Pott","year":"2006","journal-title":"Blood"},{"issue":"13","key":"2019111520524154000_B13","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/20\/3132\/1502745\/advancesadv2019000526.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/20\/3132\/1502745\/advancesadv2019000526.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T23:38:19Z","timestamp":1573861099000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/20\/3132\/422496\/Fiveyear-outcomes-of-the-S1106-study-of-RhyperCVAD"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,22]]},"references-count":13,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2019,10,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000526","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,22]]}}}